Clear — Overview
PILLAR 4 · SURVEILLANCE AFTER CURATIVE-INTENT TREATMENT
Clear is OnKommon’s molecular residual disease (MRD) service — continuous surveillance for people who have completed curative-intent treatment and want the earliest possible warning if cancer returns. It watches, in the background, for the faint molecular signal of disease long before a scan could see it, so that if something changes, you and your team can act early.
Decoder · MRD (molecular residual disease)
After surgery or curative-intent treatment, scans may look clear even when a tiny number of cancer cells remain — too few to see. Those cells can still shed ctDNA into the blood. Molecular residual disease (MRD) testing looks for that trace ctDNA, so a return of cancer can often be flagged months before it would appear on imaging.
2 · Why it matters
After curative-intent treatment, Clear offers the earliest possible warning and peace of mind.
Earlier warning
Trace ctDNA can flag returning disease months ahead of imaging — when more options may be open.
Peace of mind
Between scans, Clear offers reassurance grounded in molecular data, not just waiting.
Personalised follow-up
Results can inform how closely you are watched and when to investigate.
3 · Clear vs Sentinel
After treatment vs during treatment.
After treatment (Clear)
Clear is for the period after curative-intent treatment, when scans are clear and the goal is to catch any return as early as possible (MRD surveillance).
During treatment (Sentinel)
Sentinel is for people on active treatment for advanced disease, watching whether therapy is working and flagging resistance.
Same liquid-biopsy science, two different chapters of the journey.
4 · The two Clear tests
Clear Blood or Clear Solid — choose the right test for your cancer.
Clear Blood
- For: Blood-based / haematological contexts — leukaemia, lymphoma, myeloma.
- Sample: Blood draw
- Purpose: MRD surveillance
Clear Solid
- For: Solid tumours after curative-intent treatment — lung, breast, colon, prostate, and others.
- Sample: Blood draw
- Purpose: MRD surveillance
5 · How it works
Continuous surveillance, planned intervals.
Establish Baseline
A baseline is established, then Clear monitors at planned intervals as a subscription.
Monitor at Intervals
Each result is interpreted in context; a rising or newly-detected signal triggers a clinician review through KPCIRC, not an automated alarm.
Clinician Review
Each result is interpreted in context; a rising or newly-detected signal triggers a clinician review through KPCIRC, not an automated alarm.
6 · Pricing
Clear is offered as a monitoring subscription.
Clear is offered as a monitoring subscription. The schedule and price are confirmed at consultation based on your cancer type and follow-up plan.
RESEARCH & EVIDENCE
The science behind this
Clear uses ctDNA-based MRD detection — among the most actively validated ideas in oncology today.
Study 1 · Post-surgery ctDNA predicts recurrence
In stage II colon cancer, detectable ctDNA after surgery identified patients at much higher risk of recurrence — well before imaging changed.
Study 2 · Confirmed at large scale
Across 2,240 patients, ctDNA positivity during the post-surgery “MRD window” was strongly associated with worse disease-free and overall survival.
Study 3 · It can guide treatment intensity
A randomized trial showed a ctDNA-guided approach let many patients safely avoid adjuvant chemotherapy without a higher recurrence rate.
These independent, peer-reviewed studies describe the class of technology OnKommon uses. They are shared for education; they are not results for any individual and are not a promise of benefit.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
TRANSPARENCY — WHAT WE DO AND DON’T
Being clear about our limits
What we DO
- Watch for returning disease after curative-intent treatment
- Often flag recurrence earlier than routine imaging
- Trigger a KPCIRC clinician review on a changing signal
- Personalise how closely follow-up is done
What we DON'T do
- Diagnose recurrence on its own — findings are confirmed
- Detect every recurrence (some tumours shed little ctDNA)
- Replace your scheduled scans and specialist follow-up
- Guarantee that acting earlier will change the outcome
Clear is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A “not detected” or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →